keyword
MENU ▼
Read by QxMD icon Read
search

David dodick

keyword
https://www.readbyqxmd.com/read/29762872/the-effect-of-onabotulinumtoxina-on-aura-frequency-and-severity-in-patients-with-hemiplegic-migraine-case-series-of-11-patients
#1
Tiffany Y Chen, Ivan Garza, David W Dodick, Carrie E Robertson
BACKGROUND: OnabotulinumtoxinA has been demonstrated to be effective for the preventive treatment of headache in individuals with chronic migraine and has been approved and recommended for this patient population. While the therapeutic effect of onabotulinumtoxinA on migraine headache is well documented, there is limited information on the effect of onabotulinumtoxinA on migraine aura. OBJECTIVE: Given the prolonged and often debilitating nature of aura in patients with hemiplegic migraine, our group sought to examine the effect of onabotulinumtoxinA on aura frequency and severity in this specific subset of migraine patients...
May 15, 2018: Headache
https://www.readbyqxmd.com/read/29722276/sustained-reductions-in-migraine-days-moderate-to-severe-headache-days-and-days-with-acute-medication-use-for-hfem-and-cm-patients-taking-fremanezumab-post-hoc-analyses-from-phase-2-trials
#2
Rashmi B Halker Singh, Ernesto Aycardi, Marcelo E Bigal, Pippa S Loupe, Mirna McDonald, David W Dodick
Background In phase 2 and 3 studies, fremanezumab, a monoclonal CGRP antibody, was an effective preventive treatment for high-frequency episodic migraine (HFEM) and chronic migraine (CM). Objective Post-hoc analyses evaluated population-wise 50%, 75% and 100% responder rates, and the extent to which individual responders sustained a 50%, 75% and 100% reduction in migraine days, moderate-to-severe (M/S) headache days and days of acute medication use during all three treatment months of the fremanezumab phase 2 studies...
January 1, 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29720813/treatment-of-cluster-headache
#3
REVIEW
William S Kingston, David W Dodick
Cluster headache (CH) is a debilitating primary headache disorder. Although uncommon, affecting only 0.1% of population, it is one of the most painful conditions known to humankind. Three strategies are employed for effective treatment of CH, namely, abortive therapy, transitional therapy, and preventive therapy. Being an uncommon condition, there is a paucity of large-scale controlled trials and evidence of various therapies are based on smaller studies. This review primarily focuses on therapies with highest quality of evidence and also on the emerging therapies for CH...
April 2018: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/29697154/a-phase-by-phase-review-of-migraine-pathophysiology
#4
David W Dodick
Migraine is a common, disabling neurological disorder characterized by multiple phases: premonitory, aura, headache, postdrome, and interictal. Our understanding of the pathophysiology of each phase of migraine has evolved over recent years. The premonitory phase begins as early as 3 days before the headache phase, and involves a complex interplay between various cortical and subcortical brain regions, including the hypothalamus and brainstem nuclei that modulate nociceptive signaling. The headache phase involves activation of the trigeminovascular system, a pathway that is well characterized...
May 2018: Headache
https://www.readbyqxmd.com/read/29571276/estimating-the-clinical-effectiveness-and-value-based-price-range-of-erenumab-for-the-prevention-of-migraine-in-patients-with-prior-treatment-failures-a-us-societal-perspective
#5
Richard B Lipton, Alan Brennan, Stephen Palmer, Anthony J Hatswell, Joshua K Porter, Sandhya Sapra, Guillermo Villa, Neel Shah, Stewart Tepper, David Dodick
BACKGROUND: Frequent migraine with four or more headache days per month is a common, disabling neurovascular disease. From a US societal perspective, this analysis models the clinical efficacy and estimates the value-based price (VBP) for erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor. METHODS: A Markov health state transition model was developed to estimate the incremental costs, quality-adjusted life-years (QALYs), and value-based price range for erenumab in migraine prevention...
April 3, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29523342/migraine
#6
REVIEW
David W Dodick
Migraine is a chronic paroxysmal neurological disorder characterised by multiphase attacks of head pain and a myriad of neurological symptoms. The underlying genetic and biological underpinnings and neural networks involved are coming sharply into focus. This progress in the fundamental understanding of migraine has led to novel, mechanism-based and disease-specific therapeutics. In this Seminar, the clinical features and neurobiology of migraine are reviewed, evidence to support available treatment options is provided, and emerging drug, device, and biological therapies are discussed...
March 31, 2018: Lancet
https://www.readbyqxmd.com/read/29504483/a-multicenter-prospective-single-arm-open-label-observational-study-of-stms-for-migraine-prevention-espouse-study
#7
Amaal J Starling, Stewart J Tepper, Michael J Marmura, Ejaz A Shamim, Matthew S Robbins, Nada Hindiyeh, Andrew C Charles, Peter J Goadsby, Richard B Lipton, Stephen D Silberstein, Amy A Gelfand, Richard P Chiacchierini, David W Dodick
Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study...
May 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29504482/guidelines-of-the-international-headache-society-for-controlled-trials-of-preventive-treatment-of-chronic-migraine-in-adults
#8
Cristina Tassorelli, Hans-Christoph Diener, David W Dodick, Stephen D Silberstein, Richard B Lipton, Messoud Ashina, Werner J Becker, Michel D Ferrari, Peter J Goadsby, Patricia Pozo-Rosich, Shuu-Jiun Wang
Background Quality clinical trials form an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. In 2008, the Committee published the first specific guidelines on chronic migraine. Subsequent advances in drug, device, and biologicals development, as well as novel trial designs, have created a need for a revision of the chronic migraine guidelines...
April 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29471679/arise-a-phase-3-randomized-trial-of-erenumab-for-episodic-migraine
#9
David W Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lanteri-Minet, Vera Osipova, Kerry Palmer, Hernan Picard, Daniel D Mikol, Robert A Lenz
Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. Methods In this randomized, double-blind, placebo-controlled, phase 3 study, 577 adults with episodic migraine were randomized to placebo or 70 mg erenumab; 570 patients were included in efficacy analyses. Primary endpoint was change in monthly migraine days. Secondary endpoints were ≥50% reduction in monthly migraine days, change in acute migraine-specific medication treatment days, and ≥5-point reduction in Physical Impairment and Impact on Everyday Activities domain scores measured by the Migraine Physical Function Impact Diary...
May 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29442191/measurement-and-implications-of-the-distance-between-the-sphenopalatine-ganglion-and-nasal-mucosa-a-neuroimaging-study
#10
Joan Crespi, Daniel Bratbak, David Dodick, Manjit Matharu, Kent Are Jamtøy, Irina Aschehoug, Erling Tronvik
BACKGROUND: Historical reports describe the sphenopalatine ganglion (SPG) as positioned directly under the nasal mucosa. This is the basis for the topical intranasal administration of local anaesthetic (LA) towards the sphenopalatine foramen (SPF) which is hypothesized to diffuse a distance as short as 1 mm. Nonetheless, the SPG is located in the sphenopalatine fossa, encapsulated in connective tissue, surrounded by fat tissue and separated from the nasal cavity by a bony wall. The sphenopalatine fossa communicates with the nasal cavity through the SPF, which contains neurovascular structures packed with connective tissue and is covered by mucosa in the nasal cavity...
February 13, 2018: Journal of Headache and Pain
https://www.readbyqxmd.com/read/29431168/king-devick-test-identifies-real-time-concussion-and-asymptomatic-concussion-in-youth-athletes
#11
Priya S Dhawan, Danielle Leong, Lisa Tapsell, Amaal J Starling, Steven L Galetta, Laura J Balcer, Trenton L Overall, Jennifer S Adler, Rashmi B Halker-Singh, Bert B Vargas, David Dodick
Background: Sports concussion has an annual incidence of approximately 3.8 million. Over half go unreported and a substantial number may be asymptomatic. A rapid, cost-effective, and reliable tool that facilitates diagnosis of concussion is needed. The King-Devick (K-D) test is a vision-based tool of rapid number naming for assessment of concussion. In this study, we evaluated the utility of the K-D test in real time for identification of symptomatic concussion in youth athletes and to determine if similar impairment (subclinical concussion) exists in youth athletes without an obvious head injury or symptoms...
December 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29369967/lateralized-kappa-opioid-receptor-signaling-from-the-amygdala-central-nucleus-promotes-stress-induced-functional-pain
#12
Kelsey M Nation, Milena De Felice, Pablo I Hernandez, David W Dodick, Volker Neugebauer, Edita Navratilova, Frank Porreca
The response of diffuse noxious inhibitory controls (DNIC) is often decreased, or lost, in stress-related functional pain syndromes. Because the dynorphin/kappa opioid receptor (KOR) pathway is activated by stress, we determined its role in DNIC using a model of stress-induced functional pain. Male, Sprague-Dawley rats were primed for 7 days with systemic morphine resulting in opioid-induced hyperalgesia. Fourteen days after priming, when hyperalgesia was resolved, rats were exposed to environmental stress and DNIC was evaluated by measuring hind paw response threshold to noxious pressure (test stimulus) after capsaicin injection in the forepaw (conditioning stimulus)...
May 2018: Pain
https://www.readbyqxmd.com/read/29297655/the-emerging-role-of-gammacore-in-the-management-of-cluster-headache-expert-panel-recommendations
#13
Stephen D Silberstein, Anne H Calhoun, Christina Treppendahl, David W Dodick, Alan M Rapoport, Avinash Mamidi, Peter Vargas, Thomas H Ebert, Stewart J Tepper
A panel of 9 experts, including neurologists, other headache specialists, and medical and pharmacy directors, from 4 health plans (1 integrated delivery network and 3 plans with commercial, Medicare, and Medicaid lines of business), convened to discuss cluster headache (CH). Topics covered included the current treatment landscape, treatment challenges, economic impact of disease, and gaps in care for patients with CH. One major challenge in the management of CH is that it is underrecognized and frequently misdiagnosed, leading to delays in and suboptimal treatment for patients who suffer from this painful and disabling condition...
November 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29274037/depicting-the-pterygopalatine-ganglion-on-3-tesla-magnetic-resonance-images
#14
Daniel Fossum Bratbak, Mari Folvik, Ståle Nordgård, Lars Jacob Stovner, David W Dodick, Manjit Matharu, Erling Tronvik
PURPOSE: The pterygopalatine ganglion has yet not been identified on medical images in living humans. The primary aim of this study was to evaluate whether the pterygopalatine ganglion could be identified on 3 T MR imaging. METHODS: This study was performed on medical images of 20 Caucasian subjects on both sides (n = 40 ganglia) with an exploratory design. 3 T MR images were assessed by two physicians for the presence and size of the pterygopalatine ganglion...
December 22, 2017: Surgical and Radiologic Anatomy: SRA
https://www.readbyqxmd.com/read/29171818/fremanezumab-for-the-preventive-treatment-of-chronic-migraine
#15
RANDOMIZED CONTROLLED TRIAL
Stephen D Silberstein, David W Dodick, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi
BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine. METHODS: In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single dose of 675 mg at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), or matching placebo...
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29144718/the-emerging-role-of-gammacore%C3%A2-in-the-management-of-cluster-headache-expert-panel-recommendations
#16
Stephen D Silberstein, Anne H Calhoun, Christina Treppendahl, David W Dodick, Alan M Rapoport, Avinash Mamidi, Peter Vargas, Thomas H Ebert, Stewart J Tepper
A panel of 9 experts, including neurologists, other headache specialists, and medical and pharmacy directors, from 4 health plans (1 integrated delivery network and 3 plans with commercial, Medicare, and Medicaid lines of business), convened to discuss cluster headache (CH). Topics covered included the current treatment landscape, treatment challenges, economic impact of disease, and gaps in care for patients with CH. One major challenge in the management of CH is that it is underrecognized and frequently misdiagnosed, leading to delays in and suboptimal treatment for patients who suffer from this painful and disabling condition...
November 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28885053/board-walk-september-2017
#17
David W Dodick
No abstract text is available yet for this article.
September 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28862758/fremanezumab-as-add-on-treatment-for-patients-treated-with-other-migraine-preventive-medicines
#18
Joshua M Cohen, David W Dodick, Ronghua Yang, Lawrence C Newman, Thomas Li, Ernesto Aycardi, Marcelo E Bigal
BACKGROUND: Fremanezumab (formerly TEV-48125) is a monoclonal antibody directed against calcitonin-gene-related peptide (CGRP), a validated target for migraine preventive therapy. In two previous phase 2 studies, fremanezumab administered once every 28 days for 12 weeks was found to be effective and safe as a preventive treatment for patients suffering from episodic migraine (EM) and chronic migraine (CM). OBJECTIVE: To evaluate the efficacy and safety of fremanezumab as an add-on preventive therapy in individuals with EM and CM who are on stable doses of preventive migraine medications...
October 2017: Headache
https://www.readbyqxmd.com/read/28835404/erenumab-amg-334-in-episodic-migraine-interim-analysis-of-an-ongoing-open-label-study
#19
Messoud Ashina, David Dodick, Peter J Goadsby, Uwe Reuter, Stephen Silberstein, Feng Zhang, Julia R Gage, Sunfa Cheng, Daniel D Mikol, Robert A Lenz
OBJECTIVE: To assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (EM). METHODS: Patients enrolled in a 12-week, double-blind, placebo-controlled clinical trial (NCT01952574) who continued in an open-label extension (OLE) study will receive erenumab 70 mg every 4 weeks for up to 5 years. This preplanned interim analysis, conducted after all participants had completed the 1-year open-label follow-up, evaluated changes in monthly migraine days (MMD), achievement of ≥50%, ≥75%, and 100% reductions, Headache Impact Test (HIT-6) score, Migraine-Specific Quality of Life (MSQ), Migraine Disability Assessment (MIDAS), and safety...
September 19, 2017: Neurology
https://www.readbyqxmd.com/read/28747062/re-placebo-responses-in-device-studies
#20
Peter J Goadsby, David W Dodick, Richard B Lipton
No abstract text is available yet for this article.
January 1, 2017: Cephalalgia: An International Journal of Headache
keyword
keyword
37832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"